U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete	if Known
		Application Number	10/576,491
INFORMATION DISC	_OSURE	Filing Date	April 18, 2006
STATEMENT BY AP	LICANT	First Named Inventor	Wu
(use as many sheets as n	cessary)	Art Unit	1652
		Examiner Name	S. Swope
Sheet 1 of	2	Attorney Docket Number	10178,204-US

	U.S PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number  Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		5,880,080	03-09-1999	Amory et al				
		5,453,372	09-26-1995	Vetter et al				
		5,543,302	08-06-1996	Boguslawski et al				
	_							

			PATENT DOCU	MENTS		
Examiner	Cite,	Foreign Patent Document  Country Code 3 – Number 4 – Kind Code 5 (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	-
	1101	AU 604640	02-05-1987	Henkel		
		EP 0130756	01-09-1985	Genentech		
		WO 87/04461	07-30-1987	Amgen		
		WO 87/05050	08-27-1987	Genex		
		EP 0260105	03-16-1988	Genencor		
		WO 88/08028	10-20-1988	Genex		
		WO 88/08033	10-20-1988	Amgen		
		WO 95/30011	11-09-1995	The Procter & Gamble		
				Company		
		WO 95/30010	11-09-1995	The Procter & Gamble		
				Company		
		WO 95/29979	11-09-1995	The Procter & Gamble		
				Company		
		EP 0251446	01-07-1988	Genentech		
		WO 89/06279	07-13-1989	Novo Industri		
		WO 91/00345	01-10-1991	Novo Nordisk		
		WO 94/02618	02-03-1994	Gist-Brocades		
		WO 89/06270	07-13-1989	Novo Industri		
		WO 94/25583	11-10-1994	Novo Nordisk A/S		
						_

Examiner	Date	
Signature	Considered	

EXAMINE: Initial inference considered, whether or not clattor is in conformance with MEPPD. Dave has brough clatter in conformance and not considered produce copy of this joint with the commissional to applicate.

\*\*The conformation of the confor

Telectrical for plants floating and the plants floatin

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	or form 1449A/PTO			Complete it	e if Known		
				Application Number	10/576,491		
	INFORMATION D	DISCLOSURE		Filing Date	April 18, 2006		
	STATEMENT BY	APPLICANT		First Named Inventor	Wu		
	(use as many sheet	s as necessary)		Art Unit	1652		
				Examiner Name	S. Swope		
Sheet	2	of	2	Attorney Docket Number	10178 204-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher	T <sup>2</sup>
		RUSSELL ET AL, Rational Modification of Enzyme Catalysis by Engineering Surface Charge, Nature, Vol. 328, pages 496-500 (1987)	
		RUSSELL ET AL, Electrostatic Effects on Modification of Charged Groups in the Active Site Cleft of Subtilisin by Protein Engineering, Journal of Molecular Biology, Vol. 193, pages 803- 813 (1987)	
		THOMAS ET AL, Tailoring the PH Dependence of Enzyme Catalysis Using Protein Engineering, Nature, Vol. 318, pages 375-376 (1985)	
Examiner		Date	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Signature

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the incividual case. Any comments on the amount of time voy care required to complete this form should be sent to the Criteria Information Cliffice, VLS, Patient and Trademark. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patients, Washington, DC 20231.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.